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Abstract
Purpose Evaluation of body mass index (BMI) at final
height (FH) and annual BMI increase in adult childhood
cancer survivors (CCS) after treatment with anthracyclines,
platinum, and/or radiotherapy.
Methods BMI(weight/height²)wascalculatedretrospectively
from diagnosis until FH. The prevalence of underweight
(BMI<18.5kg/m
2) and overweight (BMI≥25 kg/m
2)/obesity
(BMI≥30 kg/m
2) at FH was compared with age-matched
controls. The association between underweight/overweight
at FH and treatment was assessed by multivariate logistic
regression. Annual BMI increase after treatment was
assessed by multilevel analysis. Analyses were adjusted
for age and underweight/overweight at diagnosis, and age
at FH.
Results At FH theprevalenceof overweight hadnotincreased,
while CCS experienced more underweight as compared to
controls (14% vs. 4%, P<0.001). Overweight at FH was
associated with cranial/craniospinal radiotherapy (CRT; OR,
2.23; 95% CI, 1.17–4.26) and underweight at FH with
anthracyclines>300 mg/m
2 (OR, 2.84; 95% CI, 1.33–6.06).
Annual BMI increase was +0.47 (0.34–0.60) kg/m
2/year. In
CCS, the annual BMI increase was greater in those with
CRT≥30 Gy as compared with those with less or no CRT
(+0.15 kg/m
2/year [0.04–0.25 kg/m
2/year], P=0.008) and
smaller in those with a higher cumulative anthracycline
dose (−0.03 kg/m
2/year [−0.05 to −0.0005 kg/m
2/year] per
100 mg/m
2, P=0.046).
Conclusions After treatment with anthracyclines, platinum,
and/or radiotherapy, CRT-treated survivors have more
overweight at FH, and a greater annual BMI increase,
while anthracycline-treated survivors have more under-
weight at FH and a lower annual BMI increase.
Keywords BMI.Body composition.Childhood cancer
survivors.Longitudinal evaluation.Underweight.
Overweight
Introduction
Overweight and obesity are well-recognised late effects of
childhood cancer treatment, especially in survivors of acute
lymphoblastic leukaemia and brain tumours [1–3]. Because
of its association with cardiovascular disease, the implica-
tions for childhood cancer survivors (CCS) are important, as
many of them are at risk for treatment-related cardiac and
cardiovascular disease, in particular after treatment with
anthracyclines and/or mediastinal irradiation [4–8]. Recently,
late cardiovascular events have also been described in long-
term survivors of testicular cancer treated with platinum-
based chemotherapy [9, 10]. In addition, vascular damage is
known to be induced by therapeutic irradiation [11, 12]. It
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DOI 10.1007/s00520-010-1080-xhas been found that CCS who received irradiation of the
brain and/or neck are at increased risk for stroke [13].
Abnormal body composition is considered a modifiable
disorder that may play a role in intervention strategies for
treatment-related cardiovascular disease; therefore, we need
an understanding of the timing of its development [14].
We performed a retrospective longitudinal evaluation of
body mass index (BMI) in a cohort of childhood cancer
survivors who had been subjects of a study on cardiovascular
disease after treatment with anthracyclines, platinum, and/or
radiotherapy. The objectives of this BMI sub-study were: (1)
toassessbodycomposition, reflected by BMI after attainment
of final height (FH); (2) to assess the association between
over- and underweight at FH and treatment variables; and (3)
toassesstheannualBMIincreasefromendoftreatmenttoFH
and its association with treatment variables.
Patients and methods
Study participants and data
Participants were included within the scope of a single-centre
study on cardiovascular disease and cardiovascular risk
factors in adult CCS, initiated in 2004, with the following
eligibility criteria: (1) diagnosis between 1976 and 1999 and
at least 5 years off-treatment; (2) treatment with potential
cardiovascular toxicity (anthracyclines, platinum, and/or
radiotherapy (RT) of head, neck, spine, or trunk); (3) age at
diagnosis≤20 years; and (4) no pre-existent cardiovascular
disease and/or Down syndrome. Eligibility for the analysis of
BMI was limited tothose participantsfor whomthe following
data were available: weight and height at the end of treatment
and at FH. Annual BMI increase was assessed if at least three
BMI calculations were available throughout a follow-up
period of 3 years or more before attainment of FH. If patients
had been treated for a relapse, the date of termination of the
last treatment was considered as end of treatment. Some
survivors had suffered from several relapses and had
prolonged intervals between treatments; in these patients the
positive effects on BMI of prolonged treatment-free intervals
andthe negativeeffectsofsubsequenttreatmentperiods could
not be discerned. Therefore, patients for whom all treatments
had covered 5 years or more were excluded from the BMI
analysis. CCS with a relapse after 5 years or a secondary
tumourwerecensoreduntil1yearbeforetheoccurrenceofthe
late relapse or secondary tumour.
Methods
Height and weight at diagnosis, at completion of treatment, at
several time points post-treatment and at FH were collected
retrospectively from the medical records. BMI was calculated
using the formula: weight/height² (kg/m²). For adults (age≥
18 years), underweight was defined as a BMI<18.5 kg/m²,
overweightasaBMI≥25kg/m²,andobesityasaBMI≥30kg/
m². In children (age<18 years), BMI reference values of
underweight, overweight, and obesity, as previously pub-
lished [15, 16], were used. Final height (FH) was defined as
the standing height reached when height had increased less
than 1.5 cm in two consecutive years of measurement [17].
If more than one BMI calculation was available after FH, we
used the first one after 5 years post-treatment.
The prevalence of underweight, overweight, and obesity at
FH in the survivors was compared with the prevalence of
underweight, overweight, and obesity in age- and sex-
matched participants of a prospective cohort study of 3,162
newborn babies (date of birth 1975–1978) . These individuals
werefollowedfor18–22yearstoidentifyperinatalriskfactors
for the development of hyperresponsiveness, lung function,
and atopy. A random sample of 590 of these individuals had
assessment of height and weight at median age 21.3 years
(range, 19.7–23.4 years). The rationale for this particular
control group was that its participants and the subjects of our
study group originated from the same geographical region,
had the same socioeconomic background and were more or
less contemporary with comparable demographics [18, 19].
Diagnosis
Given the extended time period when the cancer in our
cohort was diagnosed (1976–1999), treatment by diagnosis
had been administered according to many different proto-
cols and consequently has been very heterogeneous. For
instance, the leukaemia diagnostic group includes patients
with and without cranial irradiation, as does the brain
tumour diagnostic group. Therefore we considered it not
appropriate to evaluate the association between BMI status
and diagnosis, but to focus on the association of BMI status
and treatment variables.
Treatment variables
Becauseoftheassumedlatecardiacandvasculartoxiceffects,
the chemotherapy categories that were examined were (1)
anthracycline-based (doxorubicin, daunorubicin) combina-
tion chemotherapy, and (2) platinum-based (cisplatin, carbo-
platin) combination chemotherapy. The radiotherapy fields
that were considered were (1) cranial/craniospinal RT (CRT),
(2) chest/neck RT, including mantle field, mediastinum, total
lung, neck and/or spine, (3) abdominal RT, including
abdomen, pelvic and/or spine, and (4) total body irradiation
(TBI). Given the time period when the cancer was diagnosed
in our cohort (1976–1999), individual dosimetry on cranial
structures was not available. Therefore, CRT dose was
subdivided into <30 Gy and ≥30 Gy.
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Additional variables that could impact the development of
underweight or overweight in CCS are treatment intensity,
chronic health conditions (e.g. renal dysfunction), cardio-
vascular disease, and family history of obesity/overweight.
Therefore we retrospectively recorded the numbers of
participants with (1) neutropenic periods with fever as an
expression of treatment intensity, (2) glomerular filtration
rate (GFR) <70 ml/min as an expression of renal function,
(3) shortening fraction (SF) <29% and NYHA DC class 2
or more as an expression of cardiovascular disease, and (4)
Karnovsky score≤80% as an expression of general health
status.
Data analysis and statistics
Statistical analyses were performed using SPSS Inc.
version 14. For descriptive analyses, non-parametric tests
(Mann–Whitney and Wilcoxon tests) and median (range)
were used, since the parameters had a non-Gaussian
distribution. The prevalence of underweight, overweight,
and obesity at FH were compared with the reference
population. Since the numbers of survivors with obesity
were small, survivors with obesity and with overweight
were analysed as one group. The primary outcome
measurements were underweight and overweight at FH.
Univariate analysis was performed to compare treatment
variables and additional variables among the survivors
with normal weight, underweight, and overweight at FH.
Logistic regression analyses were used to assess the
association between the dependent variables overweight,
normal weight, and underweight at FH, and the treatment
variables. The treatment variables were tested in separate
models with adjustment for possible confounders, that is,
age at diagnosis, gender, age at BMI measurement at FH,
durationofcancertreatment,andunderweightandoverweight
at diagnosis. Since several studies have shown different
outcomes by gender [1, 20], the possible effect modification
by gender was investigated by introducing an interaction
variable between gender and the treatment variables in the
regression analysis. BMI at completion of treatment and the
annual BMI increase afterwards until FH were assessed in
association with the treatment variables using multilevel
analyses [21]. Two-sided p values≤0.05 were considered
significant.
Results
Of 1,375 (male/female [M/F] ratio, 1:3) newly diagnosed
childhood cancer patients between 1976 and 1999, 985
(M/F ratio, 1:3) survived≥5 years after diagnosis.
Diagnoses at first presentation and at 5 years survival
were : leukemia 33,4% and 33,6%; brain tumours 21,3%
and 20,1%; sarcomas 15,8% and 14,2%; malignant
lymphomas 13,6% and 16,4%; blastomas (nefroblastoma,
neuroblastoma, hepatoblastoma) 12,6% and 4,4%; germ
cell tumours 2,5% and 3%; other 0,6% and 0,4%. Of
these 985 5-year survivors, 467 met the eligibility criteria
for the study on cardiovascular disease and cardiovascu-
lar risk factors in adult CCS as described above and 377/
467 CCS fulfilled the inclusion criteria for the BMI study
(M/F 1,2). Of these 377 survivors who were eligible for the
BMIstudy,sufficientdata(e.g.threeormoreBMIscoveringa
follow-up period of three or more years, see Methods section)
for analysis of annual BMI increase were available in 299
survivors (Fig. 1). Participants' characteristics are summar-
ised in Table 1. The median (range) age at diagnosis was 9.3
(0.0–20.5) years and at the time of the first available BMI
assessment after attainment of FH at≥5 years post-treatment
it was 20.0 (12.7–42.7) years.
Prevalence of underweight and overweight at FH
The prevalence of overweight (19% [73/377] vs. 22% [128/
590]; P=0.384) and obesity (5% [17/377] vs. 5% [27/590];
P=0.961) in the CCS were comparable to those in the
reference population [18, 19], whereas the prevalence of
underweight was higher in the CCS (14% [53/377] vs. 4% [25/
590]; P<0.001). If the CCS were analysed without those with
limb amputations, the results were not statistically different.
Underweight and overweight at FH and treatment variables
The characteristics of the CCS with overweight (n=73)
were compared with those with underweight at FH (n=53)
and those with normal weight (n=251; Table 1). Survivors
with overweight at FH were more often overweight at
diagnosis compared to CCS with underweight at FH (15/67
vs. 1/48; p=0.002) and had been treated more often with
CRT (40/73 vs. 13/53; p=0.001). CCS with underweight at
FH were underweight more often at diagnosis as compared
to those with overweight at FH (28/48 vs. 10/67; p<0.001),
had received a higher cumulative anthracycline dose (183
vs. 125 mg/m
2; p=0.036), and had been treated more often
with TBI (8/53 vs. 2/73; p=0.017).
Overweight at FH From the potential confounders, over-
weight at diagnosis (odds ratio [OR] 21.13; 95% confi-
dence interval [CI] 6.40–69.78; P<0.001), underweight at
diagnosis (OR, 0.33; 95% CI, 0.15–0.72; P=0.006), and
age at BMI measurement (OR, 1.14; 95% CI, 1.06–1.22;
P<0.001) were associated with overweight at FH. There
was no association with duration of treatment. In the adjusted
models (including adjustment for overweight at diagnosis),
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dose was ≥30 Gy (Table 2). Simultaneous inclusion of CRT,
TBI, and cumulative anthracycline dose>300 mg/m² in one
model showed that overweight at FH was associated with
CRT (OR, 2.27; 95% CI, 1.13–4.55).
Underweight at FH From the potential confounders described
in the Methods section (paragraph data analysis and statistics),
underweight at diagnosis was associated with under-
weight at FH (OR, 3.69; 95% CI, 1.91–7.09; P<0.001).
There was no association with duration of treatment. In the
adjusted models (including adjustment for underweight at
diagnosis), underweight at FH was associated with TBI,
CRT, and cumulative anthracycline dose, especially if
anthracycline dose was >300 mg/m² (Table 2). Simultaneous
i n c l u s i o no fT B I ,C R T ,a n dc u mulative anthracycline dose>
300 mg/m² in one model showed that underweight at FH was
associated with cumulative anthracycline dose>300 mg/m²
(OR, 2.28; 95% CI, 1.02–5.09; Table 2).
The introduction of interaction variables between gender
and the treatment variables showed no significant differ-
ence between males and females with respect to the effect
of the treatment variables on the prevalence of overweight
and underweight at FH.
Underweight and overweight at FH and additional variables
Data on additional variables were missing in a considerable
number of subjects. The number of CCS with at least one
neutropenic period with fever was 159 out of 371 evaluable
subjects; 3 out of 254 evaluable subjects had GFR<70 ml/
min; 89 out of 246 evaluable subjects had SF<29%; 10 out
of 254 evaluable subjects had NYHA DC class 2 and none
had class 3; 4 out of 254 evaluable subjects had Karnovsky
score≤80%; 86 out of 257 evaluable subjects had a family
history of overweight/obesity. None of these additional
variables showed a significant association with overweight/
underweight at FH.
BMI increase post-treatment in association with treatment
variables
Of the 377 survivors that were eligible for the BMI
study sufficient data (see Methods section) for analysis
of annual BMI increase were available in 299 (79%). If
adjusted for age, underweight and overweight at diagnosis,
and gender, BMI at completion of treatment was associated
with CRT (estimated BMI [Est.], +0.59 kg/m² compared with
non-CRT-treated survivors; Table 3). The annual BMI
increase post-treatment until FH showed an estimated BMI
increase of +0.47 kg/m²/year (0.34–0.60 kg/m²/year) for the
entire study population. If adjusted for age, underweight and
overweight at diagnosis, and gender, there was an inverse
association of annual BMI increase with cumulative anthra-
cycline dose (Est., −0.03 kg/m²/year per 100 mg/m²; Table 3).
Annual BMI increase in CCS with and without CRTwas not
significantly different (P=0.09;Table3). Within the group of
CCS with CRT, those who received 30 Gy or more had a
greater annual BMI increase compared to those who
received a lower dose or no CRT (Est., +0.15 kg/m²/year;
95% CI, 0.04–0.25; P=0.008; Table 3).
Fig. 1 In- and exclusion of
childhood cancer survivors who
survived ≥5 years post-diagnosis
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The current study provides cross-sectional and longitudinal
BMI estimations as well as an estimation of annual BMI
increase in childhood cancer survivors who are at risk for
treatment-related cardiac and vascular late effects.
We found no difference in overweight between the entire
group of survivors and the reference population, whereas the
prevalence of underweight had increased. Within the study
population, survivors with overweight at FH had a higher
prevalence of overweight at diagnosis. In the adjusted models
(including overweight at diagnosis), overweight at FH was
associatedwith CRT, especiallyifthe CRT dosewas 30 Gyor
more. Survivors who received CRT≥30 Gy also had a higher
rate of BMI increase after completion of treatment until FH,
which is in accordance with the higher prevalence of
overweight at FH in these subjects. The association of
overweight and CRT is well known, has been described by
several authors, and has been suggested to be the result of
neuroendocrine impairment [1, 3, 22, 23]. However, only a
limited number of studies are available on BMI evaluations
at several time points during and/or after childhood cancer
Table 1 Characteristics of participants with normal weight, underweight, and overweight at FH; relationship to treatment variables
Total Underweight Normal weight Overweight p value underweight vs.
overweight
Number 377 53 251 73
Male/female 209/168 31/22 140/111 38/35 0.47
Age at diagnosis (years)
a 9.3 (0.0–20.5) 9.5 (0.0–19.5) 9.4 (0.4–20.5) 8.0 (1.1–20.1) 0.89
Age at first BMI available
after FH (years)
a
20 (12.7–42.7) 19.7 (15.6–28.4) 20.0 (12.7–42.7) 20.0 (12.8–41.7) 0.07
Follow-up post-treatment
at FH (years)
a
8.4 (5.0–28.0) 8.5 (5.0–23.5) 7.9 (5.0–25.2) 10.5 (5.0–28.0) 0.10
Diagnoses
Leukaemia 151 17 97 37
Brain tumour 47 4 30 13
Sarcoma 70 16 46 8
Malignant lymphoma 75 8 55 12
Blastoma 28 8 18 2
Germ cell tumour 6 0 5 1
Treatment variables
Anthracyclines
b 264 39 180 45 0.16
Cumulative dose
anthracyclines mg/m
2a
183 (0–640) 160 (0–600) 125 (0–600) 0.04
Anthracyclines>300 mg/m
2b 67 18 38 11 0.01
Platinum
b 32 6 21 5 0.53
c
Cranial/craniospinal irradiation
b 148 13 95 40 0.001
1–29 Gy 82 8 52 22 0.05
≥30 Gy 66 5 43 18 0.03
Chest/neck irradiation
b 90 13 58 19 0.85
Abdominal irradiation
b 80 15 47 18 0.65
Total body irradiation
b 22 8 12 2 0.017
c
Duration of treatment (years)
a 1.3 (0.1–4.9) 1.4 (0.2–4.9) 1.2 (0.1–4.2) 1.5 (0.1–4.6) 0.95
Underweight at diagnosis 107/344
d 28/48
e 69/229
f 10/67
g <0.001
Overweight at diagnosis 19/344
d 1/48
e 3/229
f 15/67
g 0.002
BMI body mass index, FH final height
aMedian (range)
bNumbers
cFisher's exact test
dMissing data at diagnosis n=33
eMissing data at diagnosis n=5
fMissing data at diagnosis n=22
gMissing data at diagnosis n=6
Support Care Cancer (2012) 20:311–318 315treatment [2, 3, 17, 24, 25], while studies assessing the rate
of BMI increase are even scarcer [17, 23]. Razzouk et al.
studied the rate of BMI increase in survivors of a
haematological malignancy and found that overweight at
diagnosis was the most significant predictor of overweight at
adult height, while no significantly different BMI increase
over time was found among patients with or without CRT
[17]. Others found that survivors who received CRT,
especially if 10 Gy or more, had a significantly greater net
increase in BMI per year in comparison with sibling
controls; however, they did not adjust for BMI at diagnosis
[23]. In the current study, we found that survivors who
received CRT, especially if ≥30 Gy, had a greater annual
BMI increase, even after adjustment for overweight at
diagnosis. Various possible underlying mechanisms have
been described for overweight in survivors [26]. One
possible hypothesis is that overweight may be the result of
a disturbed energy balance during and after childhood cancer
treatment [27, 28]. In survivors who received CRT, this
might be caused by irradiation damage to the hypothalamic-
pituitary axis [29, 30]. The hypothesis of a disturbed energy
balance is supported by our finding of a higher BMI already
evident at completion of treatment in survivors who received
CRT, suggesting that the development of an abnormal body
composition after CRT may start already during treatment
and continue after discontinuation of treatment. We did not
find an association with gender, which is not in accordance
with some other studies [17, 20].
Although our primary objective was to study overweight/
obesity in a population at high risk for cardiovascular
disorders, we found an increased prevalence of underweight
compared to the reference population. Underweight is a less
well-known late effect in childhood cancer survivors. In our
study, underweight at diagnosis was an important predictor of
underweight at FH. After adjustment for underweight at
diagnosis, we found that underweight at FH was associated
BMI at end of treatment kg/m
2 Annual BMI increase (kg/m
2/year)
Estimate (95% CI) p value Estimate (95% CI) p-value
Intercept 13.08 (1227–13.88) <0.001 0.47 (0.34–0.60) <0.001
Anthracyclines No 0 0
Yes 0.07 (−0.44–0.59) 0.78 −0.08 (−0.16–0.003) 0.06
Cumulative dose by 100 mg/m
2 −0.07 (−0.23–0.09) 0.38 −0.03 (−0.05–0.0005) 0.046
Platinum No 0 0
Yes 0.04 (−0.93–1.02) 0.93 0.05 (−0.11–0.21) 0.53
CRT No 0 0
Yes 0.59 (0.09–1.09) 0.02 0.07(−0.01–0.15) 0.09
1–29 Gy 0.91 (0.30–1.52) 0.004 0.01 (−0.09–0.11) 0.83
≥30 Gy 0.19 (−0.47–0.86) 0.57 0.15 (0.04–0.25) 0.008
TBI No 0 0
Yes −0.96 (−1.98–0.05) 0.06 0.01 (−0.15–0.17) 0.88
Table 3 Association between
annual BMI increase and
treatment by multilevel analysis
a
Dependent variables: BMI at
end of treatment and annual
BMI increase post-treatment;
independent variables:
anthracyclines, platinum,
CRT, TBI
BMI body mass index; CI
confidence interval; CRT
cranial/craniospinal irradiation;
TBI total body irradiation
aAdjusted for age, underweight,
and overweight at diagnosis, and
for gender
Underweight at FH OR (95% CI) Overweight at FH OR (95% CI)
Anthracyclines 1.09 (0.51–2.29) 0.67 (0.34–1.31)
Cumulative dose by 100 mg/m
2 1.27 (1.04–1.56) 0.94 (0.77–1.16)
Cumulative dose>300 mg/m
2 2.84 (1.33–6.06) 0.84 (0.37–1.94)
Platinum 1.40 (0.47–4.15) 0.86 (0.25–2.90)
CRT 0.34 (0.15–0.75) 2.23 (1.17–4.26)
0 Gy (reference) 1 1
1–29 Gy 0.32 (0.12–0.85) 1.98 (0.90–4.39)
≥30 Gy 0.37 (0.12–1.13) 2.55 (1.12–5.80)
Total body irradiation (TBI) 3.28 (1.11–9.68) 0.57 (0.12–2.74)
Anthracyclines >300 mg/m
2, CRT and TBI in one model:
CRT 0.45 (0.19–1.04) 2.27 (1.13–4.55)
TBI 2.88 (0.92–8.97) 0.78 (0.16–3.82)
Anthracyclines >300 mg/m
2 2.28 (1.02–5.09) 1.16 (0.48–2.81)
Table 2 Relationship between
underweight/overweight at FH
and treatment variables; logistic
regression
a
aAdjusted for age, underweight
and overweight at diagnosis,
gender and age at FH, and
duration of treatment
FH final height; OR odds ratio;
CI confidence interval; CRT
cranial/craniospinal irradiation
316 Support Care Cancer (2012) 20:311–318with a higher cumulative anthracycline dose, especially above
300 mg/m². These results are in accordance with the cross-
sectionalstudybyMeachametal.,whoalsoobservedahigher
prevalence of underweight in survivors compared with a
national reference population (6% vs. 3%). In their study,
underweight was associated with previous treatment with
anthracyclines and alkylating agents (in males and females),
abdominal RT (in males), and TBI (in females) [20]. They
stated that the majority of underweight survivors (>70%) had
an underlying problem (that is, adverse health status, a major
medical condition, and/or smoking) that contributed to their
underweight [20]. However, in that study, the association of
underweight with BMI at completion of treatment was not
evaluated. In our study, we found that BMI at completion of
treatment was not associated with anthracyclines, but that, in
those who were treated with a higher cumulative
anthracycline dose, annual BMI increase after completion
of treatment was lower compared to those who received
less or no anthracyclines. This resulted in a 1.27-fold
higher risk of underweight at FH per 100 mg/m² increase
in cumulative dose of anthracyclines, suggesting that
anthracyclines play a role in the development of
underweight in long-term CCS. However, the underlying
mechanism remains unclear.
In the general population, underweight, like overweight, is
associated with increased morbidity. Both overweight and
underweight have been described in association with in-
creased all-cause mortality [31, 32]. Calle et al. described the
association between BMI and the risk of death in a cohort of
more than one million US adults. They found a J-shaped
curve for risk of all-cause death, including cardiovascular
death; a high BMI (≥25 kg/m²) was the most predictive of
death, but the risk also increased in persons with a
BMI<20.5 kg/m² [31].
It is generally assumed that in the general population, the
mortality and morbidity due to cardiovascular disease can
be reduced by the prevention and/or treatment of
cardiovascular risk factors, such as overweight and
probably also underweight. Results from the current
study suggest that, if applied to childhood cancer
survivors, the type of cancer treatment may guide the
timing for initiation of prevention strategies. By combin-
ing the results of cross-sectional and longitudinal BMI
calculations, we were able to identify the time course of
the development of overweight or underweight in the
studied cohort of childhood cancer survivors. By doing
so, the timing of interventional strategies for survivors at
risk may be facilitated. This is a major strength of our
study. In survivors with CRT, who are already at risk for
an abnormal BMI during cancer treatment, early awareness,
prevention, and timely life-style interventions are highly
warranted.Onthe otherhand,anthracycline-treatedsurvivors,
in particular those with higher cumulative doses are at risk for
underweight after termination of treatment and therefore need
careful monitoring of nutritional status, caloric intake, and
caloric expenditure during follow-up.
Our study has several limitations. Due to the study
design, there was a selected group of patients who made
up a subset of the covering study on cardiovascular
toxicity. Also related to the study design and the
inclusion criteria, we examined only two chemotherapy
categories, anthracycline-based and platinum-based.
Therefore an unbiased analysis with respect to other
agents was troublesome and the multicollinearity of
treatment schedules precluded discrimination of the
independent effects of other chemotherapeutic agents.
Another limitation is the heterogeneity of the cohort. To
overcome this, we used regression analyses to adjust for
possibly confounding variables. In this heterogeneous
group we found no association of BMI status and
additional variables that could impact the development
of underweight or overweight in CCS, such as treatment
intensity, chronic health conditions (e.g. renal dysfunc-
tion), cardiovascular disease, and family history of
obesity/overweight.
Finally, due to the retrospective design of the study, it
was not possible to compare the annual increase in BMI
with that of healthy controls.
In conclusion, overweight and underweight at diagnosis
are important predictors of weight outcome at FH.
Moreover, even after adjustment for these variables,
survivors who received CRT had a higher BMI at
termination of cancer treatment and at FH, and survivors
with higher anthracycline doses had a lower BMI increase
after termination of treatment, which was reflected in more
underweight at FH. Health care providers and patients need
to be aware of the association of CRT with overweight and
of anthracyclines with underweight in order to enable
timely life-style changes.
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